Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts XERS Hot Sheet
Join SI Premium – FREE
Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.41), $0.03 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.09 million versus the consensus estimate of $8.21 million.
For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TransUnion (TRU) Tops Q3 EPS by 4c; Offers FY26 EPS Guidance
- UPS tops estimates as efficiency drive gains momentum
- Revolve Group (RVLV) PT Lowered to $27 at UBS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
